semaglutide and drug interactions GLP-1 Interactions: Hidden Risks Gabapentin + Semaglutide: Safety &

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned healthcare professionals to be aware of the potential risk of pulmonary aspiration in patients using glucagon-like peptide-1 (GLP-1) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GLP-1 RAs), who undergo surgery or procedures with general anaesthesia or deep sedation

The GLP-1 conversation is just beginning in Aotearoa and Im excited about the role we can play in supporting long-term health Business desk article: Our GLP-1 Support meals:

Studied in the context of: Promoting significant weight loss (clinical trials showed over 20% body weight reduction in some patients) Dramatically improving insulin sensitivity and blood sugar control Increasing energy expenditure by enhancing lipolysis (fat breakdown) and fat oxidation Suppressing appetite and cravings, leading to reduced caloric intake Slowing gastric emptying, which prolongs fullness and further curbs appetite Enhancing glucose-dependent insulin secretion (more insulin release when blood sugar is high) Reducing glucagon levels and hepatic glucose output, helping to lower fasting blood glucose Improving cardiometabolic health markers (like lowering liver fat and possibly improving cholesterol profiles)

What type of healthcare provider should you work with if you're interested in injectable obesity medications

Learn how we can help you develop products to support GI comfort, muscle health, hydration, and more for consumers engaging with GLP-1 medications.

GLP-1 medications are changing how people think about weight loss and how they actually lose weight, driving changes in views about obesity care among health systems and providers and affecting the broader US economy. These drugs hold the potential to help address what continues to be an increasing obesity problem in the US. A 2024 []